8-K: DURECT Corp Announces Late-Breaking Oral Presentation on AHFIRM Trial Data at EASL Congress 2024

DURECT Corporation will present Phase 2b AHFIRM trial data for larsucosterol in treating severe alcohol-associated hepatitis at the EASL Congress in June 2024.

Summary

• DURECT Corporation announced a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024.
• The presentation will focus on data from the Phase 2b AHFIRM trial, which evaluated larsucosterol for treating severe alcohol-associated hepatitis (AH).
• The AHFIRM trial was a randomized, double-blind, placebo-controlled study with three arms, enrolling 307 patients.
• The study compared two doses of larsucosterol (30mg and 90mg) against a standard of care (SOC) arm, which included placebo with or without methylprednisolone.
• The primary outcome was the 90-day incidence of mortality or liver transplantation, and a key secondary endpoint was 90-day survival.
• The FDA has granted larsucosterol Fast Track Designation for the treatment of AH.
• Historical data shows that mortality rates for AH are significant, with 26% at 28 days, 29% at 90 days, and 44% at 180 days in a retrospective analysis of 77 studies.
• A more recent global study reported mortality rates of approximately 20% at 28 days and 31% at 90 days for AH patients.

Sentiment

Score: 7

Explanation: The document is positive due to the acceptance of the presentation at a major conference and the FDA Fast Track designation, but it also acknowledges the risks and challenges associated with drug development and the severity of the condition being treated.

Positives

• The acceptance of a late-breaking oral presentation at the EASL Congress highlights the importance of the AHFIRM trial data.
• Larsucosterol has received Fast Track Designation from the FDA, which could expedite its development and approval.
• The AHFIRM trial is a large, international, multi-center study, which increases the reliability of the results.
• The study compares larsucosterol against a standard of care, providing a clear benchmark for efficacy.
• Larsucosterol is an epigenetic modulator with a novel mechanism of action, potentially offering a new approach to treating AH.

Negatives

• The document highlights the high mortality rates associated with AH, indicating the severity of the condition.
• Current therapies for AH, such as corticosteroids, have limitations and have not been shown to improve survival at 90 days or one year.
• Liver transplantation, while an option, is limited by organ availability and high costs, averaging over $875,000 per transplant.

Risks

• The FDA or other regulatory agencies may require more information or clinical studies for larsucosterol.
• Future clinical trials of larsucosterol may be delayed or may not demonstrate efficacy or safety.
• There is a risk that Innocoll may not commercialize POSIMIR successfully.
• The company faces risks related to the sufficiency of cash resources, anticipated capital requirements, and the need for additional financing.
• The company's ability to continue to meet the minimum bid price for continued listing on Nasdaq is a risk.
• The company's ability to obtain capital to fund operations and expenses and to continue to operate as a going concern are also risks.

Future Outlook

The company is focused on the potential development of larsucosterol for AH, MASH, and other indications, and the potential benefits of their product candidates. However, actual results may differ materially from forward-looking statements due to various risks and uncertainties.

Management Comments

• DURECT is pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer.

Industry Context

The announcement is relevant to the biopharmaceutical industry, particularly companies focused on liver diseases and epigenetic therapies. The lack of FDA-approved therapies for AH highlights the unmet medical need and the potential market for effective treatments like larsucosterol. The presentation at EASL Congress is a key event for sharing clinical trial data with the medical community.

Comparison to Industry Standards

• The AHFIRM trial's design, with a randomized, double-blind, placebo-controlled approach, aligns with industry standards for clinical trials.
• The use of a standard of care arm, including placebo with or without methylprednisolone, provides a relevant comparison for assessing the efficacy of larsucosterol.
• The study's focus on 90-day mortality and liver transplantation as primary outcomes is consistent with endpoints used in other trials for severe liver diseases.
• The historical mortality rates for AH, as cited in the document, are consistent with published data from other studies, such as the retrospective analysis of 77 studies and the global study published in December 2021.
• Companies like Gilead Sciences and Intercept Pharmaceuticals have also been developing treatments for liver diseases, but their focus is primarily on NASH/MASH, not specifically AH, making DURECT's focus on AH a differentiated approach.

Stakeholder Impact

• Shareholders may react positively to the presentation of clinical trial data at a major conference.
• Patients with severe alcohol-associated hepatitis may benefit from the development of new treatment options.
• The medical community will gain insights into the potential of larsucosterol for treating AH.
• Employees of DURECT are involved in the development of larsucosterol and the commercialization of POSIMIR.

Next Steps

• DURECT will present the AHFIRM trial data at the EASL Congress on June 8, 2024.
• The company will continue to develop larsucosterol for the treatment of AH and potentially other indications.
• The company will continue to monitor the commercialization of POSIMIR by Innocoll.

Key Dates

Keywords

larsucosterol, alcohol-associated hepatitis, AH, epigenetic therapy, AHFIRM trial, EASL Congress, liver disease, FDA Fast Track, mortality, liver transplantation